riTUXimab
Pronunciation: rit-TUCKS-ee-mab
Other Name(s): Rituxan®; Truxima™; Riximyo™; Ruxience™; Riabni™
Appearance: Clear, colourless solution
mixed into larger bags of fluids
Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.
Drug Monograph
Jun 2025
Eligibility Forms
Rituximab (Biosimilar IV) - Single Agent - Indolent Lymphoma Rituximab (Biosimilar IV) and Rituximab SC - Aggressive Histology Lymphoma Rituximab (Biosimilar IV) and Rituximab SC - HIV-Related Aggressive Histology B-cell Lymphoma Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma Rituximab (Biosimilar IV) and Rituximab SC - Previously Untreated Chronic Lymphocytic Leukemia Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma Rituximab (Biosimilar IV) and Rituximab SC - Second Line - Chronic Lymphocytic Leukemia Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma Rituximab (Biosimilar IV) - In Combination with Idelalisib - Relapsed Chronic Lymphocytic Leukemia Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Venetoclax - Relapsed Chronic Lymphocytic Leukemia Polatuzumab Vedotin with Bendamustine and Rituximab (Biosimilar) - Relapsed or Refractory Diffuse Large B-cell Lymphoma Rituximab (Biosimilar IV) - As Part of the MATRix Regimen in Newly Diagnosed Previously Untreated PCNSL Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Ibrutinib for Previously Treated Waldenstrӧms MacroglobulinemiaPatient Info Sheet
Oct 2023
What it is used for
- For treating blood cancers such as non-Hodgkin's lymphoma or chronic lymphocytic leukemia (CLL)
- Rituximab is available as a biosimilar medication. See our biosimilar pamphlet for more information.